Future Trends in Obesity Management: Perceptions of Oral GLP-1s Orforglipron & Danuglipron

Executed on:Mar 13, 2025 4:00 PM EDT

Call Duration:30 minutes

Expert Profile

ExpertBlinded Expert

Institution: Harvard Medical SchoolMedical Director, Obesity Clinic Program and Inpatient Diabetes Program & Associate Professor at Harvard Medical School.
Manages ~1,000 patients with diabetes and obesity
Research interests include diabetes and obesity, metabolic syndrome and obesity and cardiovascular disease with a focus on understanding metabolic and cardiovascular benefits of lifestyle changes and weight loss. 

Interview Goal

We would like to understand obesity management providers, PIs, and/or KOLs' perceptions of two Oral GLP-1s: Orforglipron & Danuglipron. This includes perceptions of the efficacy and safety of these therapies, including thoughts on the potential drug-drug interaction (DDI) profile of the two oral GLP-1s. Given the rapidly shifting landscape, what are KOLs' opinions on using these two therapies, and how could they be used in future treatment pathways?
 

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.